How much does Mounjaro cost without insurance?

The list price is approximately $1,023 to $1,070 per month. Retail cash prices at pharmacies can exceed $1,200 depending on location. Manufacturer direct-purchase programs and compounding pharmacies may offer lower price points.

Does insurance cover Mounjaro for weight loss?

Coverage varies. Most commercial plans require prior authorization and may impose step therapy. Medicare Part D does not cover anti-obesity medications by statute. Fewer than half of state Medicaid programs cover GLP-1s for obesity as of 2026.

What is the difference between Mounjaro and Zepbound?

Both contain tirzepatide manufactured by Eli Lilly. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is approved for chronic weight management. The molecule and dosing are identical; the indication and insurance billing pathway differ.

Can I get compounded tirzepatide?

Compounded versions have been available through accredited 503A and 503B pharmacies during FDA-recognized shortage periods. Regulatory status shifts; verify current FDA shortage designations and pharmacy accreditation before purchasing compounded tirzepatide.

What happens if I stop taking tirzepatide?

Clinical trial data from the SURMOUNT program shows that most patients regain a significant portion of lost weight within 12 months of discontinuation. The HealthRX Medical Team recommends discussing a long-term plan with your prescriber before starting therapy.

What Boy George's GLP-1 Protocol Would Cost Outside a Celebrity Context

Q: Did Boy George confirm using Mounjaro?

Yes. Boy George has publicly disclosed his use of Mounjaro (tirzepatide) for weight management. This is confirmed, not speculated.

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Boy George and Mounjaro: The Public Record

Boy George, the Grammy-winning Culture Club frontman, has openly discussed his use of Mounjaro (tirzepatide) for weight management. His public disclosure places him among a growing number of high-profile figures who have confirmed GLP-1 receptor agonist use rather than leaving it to speculation.

His candor matters for a specific reason: it puts a brand name in front of millions of people who then search for that drug. Google Trends data consistently shows celebrity disclosures correlate with spikes in GLP-1-related search queries. The gap between hearing a celebrity name a drug and understanding what it takes to actually fill that prescription is where most patients get stuck.

At a glance

Celebrity: Boy George
Drug: Mounjaro (tirzepatide)
Status: Publicly confirmed use for weight management
Drug class: Dual GIP/GLP-1 receptor agonist
FDA approval: Type 2 diabetes (2022); chronic weight management (2023, as Zepbound)
List price (2026): ~$1,050 per monthly fill without insurance
Insurance reality: Prior authorization required by most commercial plans; BMI and comorbidity thresholds apply

What Is Tirzepatide and How Does It Work?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike semaglutide (Ozempic, Wegovy), which targets only the GLP-1 receptor, tirzepatide activates both incretin pathways. This dual mechanism produced superior weight reduction in head-to-head trials, with the SURMOUNT-1 trial demonstrating up to 22.5% body weight loss at the highest dose (15 mg weekly) over 72 weeks.

The drug is administered as a once-weekly subcutaneous injection. Dosing follows a titration schedule: patients start at 2.5 mg weekly for four weeks, then increase to 5 mg. From there, the prescriber may escalate in 2.5 mg increments every four weeks up to a maximum of 15 mg, depending on tolerability and response. The FDA prescribing information specifies this titration to minimize gastrointestinal side effects, which are the most common reason patients discontinue therapy.

Common side effects include nausea (reported in 24% of participants at the 15 mg dose in SURMOUNT-1), diarrhea, constipation, and injection-site reactions. More serious but rare risks include pancreatitis and medullary thyroid carcinoma, the latter carrying a boxed warning based on rodent studies. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use tirzepatide.

The Cost Reality: What a Non-Celebrity Patient Faces

Boy George's public disclosure did not include discussion of cost. For most patients, cost is the single largest barrier to GLP-1 therapy. Here is the breakdown as of 2026.

List Price

Mounjaro's wholesale acquisition cost sits around $1,023 to $1,070 per monthly supply across all dose strengths. Zepbound (the obesity-indication brand of tirzepatide) carries a comparable price point. Retail pharmacy cash prices can exceed $1,200 depending on geography and pharmacy.

Commercial Insurance

Most commercial insurers cover tirzepatide for type 2 diabetes with prior authorization. Coverage for weight management (the Zepbound indication) is more restrictive. Typical requirements include:

BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes)
Documentation of failed lifestyle modification (diet and exercise) for 3 to 6 months
Step therapy: some plans require trial and failure of an older agent (phentermine, orlistat, or naltrexone-bupropion) before approving tirzepatide
Prior authorization, renewed every 6 to 12 months

Denial rates for GLP-1 weight management indications remain high. A 2024 analysis in JAMA Network Open found that roughly 40% of initial prior authorization requests for GLP-1 agonists used for obesity were denied, with appeal success rates varying widely by plan.

Medicare and Medicaid

Medicare Part D does not cover anti-obesity medications by statute, though legislative efforts to change this (the Treat and Reduce Obesity Act) remain in progress as of 2026. Medicaid coverage varies by state; fewer than half of state Medicaid programs cover GLP-1s for obesity.

If the patient has a type 2 diabetes diagnosis, Medicare Part D does cover Mounjaro, subject to formulary placement and prior authorization.

Manufacturer Savings Programs

Eli Lilly offers a savings card for commercially insured patients that can reduce the out-of-pocket cost to as low as $25 per month for eligible fills. Key restrictions:

Not valid for patients on government insurance (Medicare, Medicaid, Tricare, VA)
Caps on total annual savings (typically $150 per fill, up to a program maximum)
Must have commercial insurance that covers the drug; the card offsets copay, not the full price

For uninsured or cash-pay patients, Lilly has periodically offered direct-purchase programs (LillyDirect) at reduced rates, with reported prices around $550 per month for single-dose vials. Availability and pricing of these programs shift frequently.

Compounding Pharmacies

Compounded tirzepatide became available through 503A and 503B pharmacies during the FDA shortage period. Prices ranged from $150 to $450 per month depending on dose and pharmacy. The FDA's position on compounded versions once the shortage resolves remains a contested regulatory and legal question in 2026. Patients considering compounded tirzepatide should verify the pharmacy's accreditation and understand that compounded products do not undergo the same FDA review as branded medications.

The HealthRX Medical Team Take

The HealthRX Medical Team sees Boy George's disclosure as a useful entry point for a harder conversation. A celebrity confirming Mounjaro use normalizes the drug, but it can also create a distorted impression of accessibility. Boy George is not navigating step therapy, prior authorization denials, or pharmacy benefit manager formulary restrictions.

For a non-celebrity patient, the path to sustained tirzepatide therapy looks like this:

Clinical evaluation. A prescriber documents BMI, comorbidities, and prior weight management attempts. This documentation is the foundation of a prior authorization submission.
Insurance navigation. If the initial PA is denied, appeal with clinical notes, lab values, and supporting literature. The American Diabetes Association Standards of Care and Endocrine Society guidelines both support GLP-1 therapy for qualifying patients, and citing these in appeals strengthens the case.
Cost mitigation. Stack manufacturer savings cards with commercial insurance. If uninsured, explore manufacturer direct-purchase programs or accredited compounding pharmacies as a bridge.
Long-term planning. GLP-1 therapy for weight management is generally ongoing. Discontinuation leads to weight regain in most patients within a year, as demonstrated in the SURMOUNT-4 trial's off-treatment data. Patients should budget for indefinite therapy or plan a structured taper with their prescriber.

The clinical evidence for tirzepatide is strong. The SURMOUNT program showed consistent, clinically meaningful weight loss across BMI categories, with improvements in cardiometabolic markers including HbA1c, blood pressure, and lipid profiles. The question for most patients is not whether the drug works. It is whether they can afford it for the duration required to maintain results.

What Patients Should Ask Their Prescriber

Before starting tirzepatide based on a celebrity disclosure or media coverage, the HealthRX Medical Team recommends patients ask:

"Does my insurance cover tirzepatide, and which indication (diabetes vs. obesity) gives me the best chance of approval?"
"What documentation do you need from me to support a prior authorization?"
"If I'm denied, will your office handle the appeal?"
"What is my realistic out-of-pocket cost after savings cards?"
"What happens if I need to stop the medication, either by choice or because coverage changes?"

These questions matter more than the drug's celebrity association. The pharmacology is identical regardless of who injects it. The access barriers are not.

Frequently asked questions

›